Brokerages Set Atara Biotherapeutics (ATRA) Target Price at $45.33

Atara Biotherapeutics (NASDAQ:ATRA) has been given a consensus rating of “Hold” by the eleven ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, five have given a hold rating and five have given a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $45.33.

A number of brokerages recently commented on ATRA. William Blair restated an “outperform” rating on shares of Atara Biotherapeutics in a report on Tuesday, March 20th. Guggenheim began coverage on Atara Biotherapeutics in a report on Thursday, March 15th. They set a “neutral” rating for the company. Canaccord Genuity restated a “buy” rating and set a $70.00 target price on shares of Atara Biotherapeutics in a report on Tuesday, March 13th. Jefferies Group lifted their price objective on Atara Biotherapeutics from $30.00 to $46.00 and gave the company a “buy” rating in a research note on Monday, March 5th. Finally, BidaskClub cut Atara Biotherapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, March 1st.

How to Become a New Pot Stock Millionaire

In other news, CEO Isaac E. Ciechanover sold 28,700 shares of the firm’s stock in a transaction dated Friday, January 12th. The stock was sold at an average price of $21.39, for a total transaction of $613,893.00. Following the sale, the chief executive officer now owns 743,675 shares of the company’s stock, valued at approximately $15,907,208.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Carol Giltner Gallagher sold 1,183 shares of the firm’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $46.50, for a total value of $55,009.50. Following the sale, the director now directly owns 111,286 shares in the company, valued at approximately $5,174,799. The disclosure for this sale can be found here. Insiders sold a total of 292,924 shares of company stock valued at $10,482,270 in the last quarter. Company insiders own 16.20% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. SG Americas Securities LLC acquired a new stake in shares of Atara Biotherapeutics during the 3rd quarter worth about $142,000. Russell Investments Group Ltd. acquired a new stake in shares of Atara Biotherapeutics during the 3rd quarter worth about $170,000. MetLife Investment Advisors LLC acquired a new stake in shares of Atara Biotherapeutics during the 4th quarter worth about $217,000. The Manufacturers Life Insurance Company raised its position in shares of Atara Biotherapeutics by 7.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock worth $285,000 after acquiring an additional 1,369 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Atara Biotherapeutics by 2.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 21,718 shares of the biotechnology company’s stock worth $304,000 after acquiring an additional 610 shares in the last quarter. 76.88% of the stock is currently owned by institutional investors and hedge funds.

Atara Biotherapeutics stock traded down $0.85 during midday trading on Wednesday, reaching $38.15. 164,040 shares of the stock traded hands, compared to its average volume of 1,063,313. Atara Biotherapeutics has a 12-month low of $11.80 and a 12-month high of $49.90. The stock has a market capitalization of $1,514.21, a price-to-earnings ratio of -9.75 and a beta of 2.54.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its earnings results on Tuesday, February 27th. The biotechnology company reported ($1.15) EPS for the quarter, meeting analysts’ consensus estimates of ($1.15). equities research analysts anticipate that Atara Biotherapeutics will post -3.62 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Brokerages Set Atara Biotherapeutics (ATRA) Target Price at $45.33” was originally reported by Enterprise Leader and is owned by of Enterprise Leader. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://theenterpriseleader.com/2018/04/02/brokerages-set-atara-biotherapeutics-atra-target-price-at-45-33.html.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply